ACTIVATED ALANINE AMINOTRANSFERASE

Transcription

1 ACTIVATED ALANINE AMINOTRANSFERASE 8L92-20 and 8L /R2 ACTIVATED ALANINE AMINOTRANSFERASE This package insert contains information to run the Activated Alanine Aminotransferase assay on the ARCHITECT c Systems and the AEROSET System. NOTE: Changes Highlighted NOTE: This package insert must be read carefully prior to product use. Package insert instructions must be followed accordingly. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert. Customer Support United States: Canada: International: ABBOTT (English speaking customers) (French speaking customers) Call your local Abbott representative Symbols in Product Labeling Concentration Authorized Representative in the European Community Ingredients In vitro diagnostic medical device Batch code/lot number Reagent 1 Catalog number/list number Serial number Consult instructions for use Manufacturer Temperature limitation Use by/expiration date Reagent 2 ABBOTT LABORATORIES Abbott Park, IL 60064, USA ABBOTT Max-Planck-Ring Wiesbaden Germany June , 2008 Abbott Laboratories 1

2 NAME ACTIVATED ALANINE AMINOTRANSFERASE INTENDED USE The Activated Alanine Aminotransferase (Activated ALT) assay is used for the quantitation of alanine aminotransferase in human serum or plasma. SUMMARY AND EXPLANATION OF TEST Alanine Aminotransferase (ALT), also referred to as glutamate pyruvate transaminase (GPT), is an enzyme involved in amino acid metabolism. It is found in many tissues, but the highest levels are found in the liver and kidney. Tissue destruction leads to the release of the intracellular enzyme into the circulating blood. Markedly elevated serum ALT levels may be found in a variety of diseases of the liver, such as hepatitis, mononucleosis, and cirrhosis. These very high levels of ALT are not usually observed in other disease processes, e.g., myocardial infarction; thus, ALT is regarded as a reasonably specific indicator of liver disease. PRINCIPLES OF PROCEDURE ALT present in the sample catalyzes the transfer of the amino group from L-Alanine to 2-Oxoglutarate, in the presence of Pyridoxal- 5'-Phosphate, forming Pyruvate and L-Glutamate. Pyruvate in the presence of NADH and Lactate Dehydrogenase (LD) is reduced to L-Lactate. In this reaction NADH is oxidized to NAD. The reaction is monitored by measuring the rate of decrease in absorbance at 340 nm due to the oxidation of NADH to NAD. L-Alanine + 2-Oxoglutarate ALT, P-5'-P Pyruvate + L-Glutamate LD Pyruvate + NADH L-Lactate + NAD + The Activated ALT reagent is based on the optimized formulation as recommended by the International Federation of Clinical Chemistry (IFCC). 1,2 Methodology: IFCC REAGENTS Reagent Kit 8L92 Activated ALT is supplied as a liquid, ready-to-use two-reagent kit which contains: 8L x 40 ml 10 x 40 ml Estimated tests per kit: 2,750* 8L x 68 ml 10 x 68 ml Estimated tests per kit: 4,820* *Calculation is based on the minimum reagent fill volume per kit. Reactive Ingredients β-nadh LD Pyridoxal Phosphate Monohydrate TRIS L-Alanine 2-Oxoglutaric Acid TRIS Concentration mmol/l 2,460 U/L mmol/l 100 mmol/l 1,025 mmol/l mmol/l 105 mmol/l REAGENT HANDLING AND STORAGE Reagent Handling Remove air bubbles, if present in the reagent cartridge, with a new applicator stick. Alternatively, allow the reagent to sit at the appropriate storage temperature to allow the bubbles to dissipate. To minimize volume depletion, do not use a transfer pipette to remove the bubbles. CAUTION: Reagent bubbles may interfere with proper detection of reagent level in the cartridge, causing insufficient reagent aspiration which could impact results. Reagent Storage Unopened reagents are stable until the expiration date when stored at 2 to 8 C. Reagent stability is 30 days if the reagent is uncapped and onboard. WARNINGS AND PRECAUTIONS Precautions for Users 1. For in vitro diagnostic use. 2. Do not use components beyond the expiration date. 3. Do not mix reagents from different kit lot numbers. 4. CAUTION: This product requires the handling of human specimens. It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Bloodborne Pathogens. 3 Biosafety Level 2 4 or other appropriate biosafety practices 5,6 should be used for materials that contain or are suspected of containing infectious agents. For reagents not classified as dangerous per European Directive 1999/45/EC as amended, safety data sheet available for professional user on request. SPECIMEN COLLECTION AND HANDLING Suitable Specimens Serum and plasma are acceptable specimens. CAUTION: Erythrocytes contain approximately seven times more ALT than does serum. 7 Hemolysis in serum or plasma can increase test results. Serum: Use serum collected by standard venipuncture techniques into glass or plastic tubes with or without gel barriers. Ensure complete clot formation has taken place prior to centrifugation. When processing samples, separate serum from blood cells or gel according to the specimen collection tube manufacturer s instructions. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may take longer to complete their clotting processes. Fibrin clots may subsequently form in these sera and the clots could cause erroneous test results. Plasma: Use plasma collected by standard venipuncture techniques into glass or plastic tubes. Acceptable anticoagulants are lithium heparin (with or without gel barrier), sodium heparin, and EDTA. Ensure centrifugation is adequate to remove platelets. When processing samples, separate plasma from blood cells or gel according to the specimen collection tube manufacturer s instructions. For total sample volume requirements, refer to the instrument-specific ASSAY PARAMETERS section of this package insert and Section 5 of the instrument-specific operations manual. Specimen Storage Serum and plasma It is recommended that specimens be assayed on the day of collection. 8,9 Numerous publications have defined storage conditions for ALT Examples are shown in the table below. Temperature Maximum Storage Bibliographic Reference 30 C 3 days 15 2 to 8 C 7 days C 60 days 20 When samples were stored at -20 C for 8 days, an 11% reduction in ALT activity was observed; a 20% reduction in ALT activity was observed when specimens were stored at -20 C for 1 month. 21 NOTE: Stored specimens must be inspected for particulates. If present, mix and centrifuge the specimen to remove particulates prior to testing. 2

3 PROCEDURE Materials Provided 8L92 Activated ALT Reagent Kit Materials Required but not Provided Control Material Saline (0.85% to 0.90% NaCl) for specimens that require dilution Assay Procedure For a detailed description of how to run an assay, refer to Section 5 of the instrument-specific operations manual. Specimen Dilution Procedures The ARCHITECT c Systems and the AEROSET System have automatic dilution features; refer to Section 2 of the instrument-specific operations manual for additional information. Serum and plasma: Specimens with ALT values exceeding 2,855 U/L (4,772 U/L for Flex Rate Linearity) are flagged and may be diluted using either the Automated Dilution Protocol or the Manual Dilution Procedure. Automated Dilution Protocol If using the Automated Dilution Protocol, the system performs a 1:5 dilution of the specimen and automatically corrects the enzyme activity value by multiplying the result by the appropriate dilution factor. Manual Dilution Procedure Manual dilutions should be performed as follows: Use saline (0.85% to 0.90% NaCl) to dilute the sample. The operator must enter the dilution factor in the patient or control order screen. The system uses this dilution factor to automatically correct the enzyme activity value by multiplying the result by the entered factor. If the operator does not enter the dilution factor, the result must be multiplied by the appropriate dilution factor before reporting the result. NOTE: If a diluted sample result is flagged indicating it is less than the linear low limit, do not report the result. Rerun using an appropriate dilution. For detailed information on ordering dilutions, refer to Section 5 of the instrument-specific operations manual. CALIBRATION Calibration is stable for approximately 30 days (720 hours) and is required with each change in reagent lot number. Verify calibration with at least two levels of controls according to the established quality control requirements for your laboratory. If control results fall outside acceptable ranges, recalibration may be necessary. A calibration factor must be entered. Refer to PARAMETERS section for the specific factor. ARCHITECT c Systems Configure assay parameters window, Calibration view AEROSET System Assay Configuration screen, Calibration page For a detailed description of how to calibrate an assay, refer to Section 6 of the instrument-specific operations manual. QUALITY CONTROL The following is the recommendation of Abbott Laboratories for quality control. As appropriate, refer to your laboratory standard operating procedure(s) and/or quality assurance plan for additional quality control requirements and potential corrective actions. Two levels of controls (normal and abnormal) are to be run every 24 hours. If more frequent control monitoring is required, follow the established quality control procedures for your laboratory. If quality control results do not meet the acceptance criteria defined by your laboratory, patient values may be suspect. Follow the established quality control procedures for your laboratory. Recalibration may be necessary. Review quality control results and acceptance criteria following a change of reagent lot. RESULTS Refer to the instrument-specific operations manual for information on results calculations. ARCHITECT System Operations Manual Appendix C AEROSET System Operations Manual Appendix A Representative performance data are given in the EXPECTED VALUES and SPECIFIC PERFORMANCE CHARACTERISTICS sections of this package insert. Results obtained in individual laboratories may vary. LIMITATIONS OF THE PROCEDURE Refer to the SPECIMEN COLLECTION AND HANDLING and SPECIFIC PERFORMANCE CHARACTERISTICS sections of this package insert. Reagent cross contamination testing for the Activated ALT assay ( 8L92) was performed on the ARCHITECT c Systems and the AEROSET System. ARCHITECT c Systems Assays affected by Activated ALT Configure Activated ALT SmartWash parameters in the following assay files on the ARCHITECT c Systems. Configure COMPONENT REAGENT / WASH VOL REP ASSAY Gent 1E11-20 Cuvette A-ALT 0.5% Acid Wash 345 EXPECTED VALUES Reference Range Serum 22 /Plasma Range (U/L) Adult 0 to 55 Published reference range studies have demonstrated that ALT activity varies with body-mass index (BMI), demographics, and geography. 23,24 Using a population rigorously selected to include only healthy subjects, investigators found upper reference limits of 19 U/L for females and 30 U/L for males. 25 Preliminary upper reference limits based on a hospitalized German population have been published for the IFCC reference procedure. For ALT, these values were 34 U/L for females and 45 U/L for males. 26 It is recommended that each laboratory determine its own reference range based upon its particular locale and population characteristics. SPECIFIC PERFORMANCE CHARACTERISTICS Linearity Activated ALT is linear up to 2,855 U/L. Flex Rate Linearity is 4,772 U/L. To use Flex Rate Linearity, the operator must edit the linear high value to 4,772 on the appropriate screen. ARCHITECT c Systems Configure assay parameters screen, Results view AEROSET System Assay Configuration screen, Outline page Linearity was verified using Clinical and Laboratory Standards Institute (CLSI) protocol NCCLS EP6-A. 27 Limit of Detection (LOD) The LOD for Activated ALT is 5 U/L. The LOD is the mean concentration of an analyte-free sample + 2 SD, where SD = the pooled, within-run standard deviation of the analyte-free sample. A study performed on an ARCHITECT c System and an AEROSET System produced an LOD for Activated ALT of 4.8 U/L. Limit of Quantitation (LOQ) The LOQ for Activated ALT is 5.7 U/L. The LOQ is the analyte concentration at which the CV = 20%. 3

4 SPECIFIC PERFORMANCE CHARACTERISTICS (Continued) Interfering Substances Interference effects were assessed by Dose Response and Paired Difference methods, at the medical decision level of the analyte. Interfering Substance Bilirubin Hemoglobin Intralipid Interferent Concentration N Target (U/L) Observed (% of Target) 30 mg/dl (513 μmol/l) mg/dl (1,026 μmol/l) mg/dl (7.5 g/l) mg/dl (10.0 g/l) mg/dl (5.0 g/l) mg/dl (7.5 g/l) Bilirubin solutions at the above concentrations were prepared by addition of a bilirubin stock to human serum pools. Hemoglobin solutions at the above concentrations were prepared by addition of hemolysate to human serum pools. Intralipid solutions at the above concentrations were prepared by addition of Intralipid to human serum pools. Interferences from medication or endogenous substances may affect results. 28 Accuracy by Recovery Precision The imprecision of the Activated ALT assay is 6.0% Total CV. Representative data from studies using CLSI protocol NCCLS EP5-A2 29 are summarized below. Control Level 1 Level 2 N Mean (U/L) Within Run Between Run Between Day Total SD %CV SD %CV SD %CV SD %CV Method Comparison Correlation studies were performed using CLSI protocol NCCLS EP9-A2. 30 Serum results from the Activated ALT assay on the AEROSET System were compared with those from the Abbott Clinical Chemistry ALT Activated (ALT-A 8D36) assay on the same system. Serum results from the Activated ALT assay on an ARCHITECT c System were compared with those from the ALT Activated (ALT-A 8D36) assay on an AEROSET System. Activated ALT vs. Abbott ALT-A on AEROSET Activated ALT on ARCHITECT vs. Abbott ALT-A on AEROSET N Y - Intercept Correlation Coefficient Slope Range (U/L) 10 to 4, to 4,564 BIBLIOGRAPHY 1. Bergmeyer HU, Horder M, Rej R. Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. J Clin Chem Clin Biochem 1986;24(7): Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 2002;40(7): US Department of Labor, Occupational Safety and Health Administration. 29 CFR Part Occupational Exposure to Bloodborne Pathogens. 4. US Department of Health and Human Services. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: US Government Printing Office; January World Health Organization. Laboratory Biosafety Manual. Geneva: World Health Organization, Sewell DL, Bove KE, Callihan DR, et al. Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline Third Edition (M29-A3). Wayne, PA: Clinical and Laboratory Standards Institute, Rej R. Aminotransferases in disease. Clin Lab Med 1989;9(4): Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th ed. St. Louis, MO: Elsevier; 2006: Cuccherini B, Nussbaum SJ, Seeff LB, et al. Stability of aspartate aminotransferase and alanine aminotransferase activities. J Lab Clin Med 1983;102(3): Williams KM, Williams AE, Kline LM, et al. Stability of serum alanine aminotransferase activity. Transfusion 1987;27(5): Henry RJ, Cannon DC, Winkelman JW. Clinical Chemistry Principles and Technics, 2nd ed. Hagerstown, MD: Harper and Row; 1974: Ruby SG, Reiber NE, Lonser RE. Pre-analytical variation in alanine aminotransferase. Clin Chem 1988;34(4) Heins M, Heil W, Withold W. Storage of serum or whole blood samples? Effects of time and temperature on 22 serum analytes. Eur J Clin Chem Clin Biochem 1995;33(4): Dale JC, Pruett SK. Phlebotomy a minimalist approach. Mayo Clin Proc 1993;68(3): Young D. Effects of Preanalytical Variables on Clinical Laboratory Tests, 2nd ed. Washington, DC: AACC Press; 1997: Elfath D, Cooney J, McDaniel R, et al. Effect of frozen storage of serum on the level of 22 chemistry analytes [Poster 0102 presented at AACC 43rd National Meeting in Washington DC: July 30, 1991]. Clin Chem 1991;37(6): Faulkner AM, Lukes-Hall AM, White GW. Evaluation of the Greiner plasma separator blood tube. Ann Clin Biochem 1990;27: Wilding P, Zilva JF, Wilde CE. Transport of specimens for clinical chemistry analysis. Ann Clin Biochem 1977;14(6): Schwartz MK. Interferences in diagnostic biochemical procedures. Adv Clin Chem 1973;16: Mosley JW, Goodwin RF. Stability of serum glutamic pyruvic transaminase activity on storage. Am J Clin Pathol 1965;44: Donnelly JG, Soldin SJ, Nealon DA, et al. Stability of twenty-five analytes in human serum at 22 C, 4 C, and -20 C. Pediatr Pathol Lab Med 1995;15(6): Murray RL. Alanine aminotransferase. In: Kaplan LA, Pesce AJ, editors. Clinical Chemistry Theory, Analysis, and Correlation, 2nd ed. St. Louis, MO: CV Mosby; 1989: Sherman KE, Dodd RY, et al. Alanine aminotransferase levels among volunteer blood donors: geographic variation and risk factors. J Infect Dis 1982;145(3): Sherman KE. Alanine aminotransferase in clinical practice. A review. Arch Intern Med 1991;151(2); Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137(1): Schumann G, Klauke R. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: preliminary upper reference limits obtained in hospitalized subjects. Clin Chim Acta 2003;327(1 2): Tholen DW, Kroll M, Astles JR, et al. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (EP6-A). Wayne, PA: The National Committee for Clinical Laboratory Standards, Young DS. Effects of Drugs on Clinical Laboratory Tests, 4th ed. Washington, DC: AACC Press; 1995: Tholen DW, Kallner A, Kennedy JW, et al. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline Second Edition (EP5-A2). Wayne, PA: The National Committee for Clinical Laboratory Standards, Krouwer JS, Tholen DW, Garber CC, et al. Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline Second Edition (EP9-A2). Wayne, PA: The National Committee for Clinical Laboratory Standards, TRADEMARKS AEROSET and ARCHITECT are registered trademarks of Abbott Laboratories. c System and SmartWash are trademarks of Abbott Laboratories. All other trademarks, brands, product names, and trade names are the property of their respective companies. 4

5 ARCHITECT c Systems ASSAY PARAMETERS Activated Alanine Aminotransferase Serum/Plasma Conventional and SI Units Configure assay parameters General General о Calibration о SmartWash о Results о Interpretation Assay: A-ALT Type: Photometric Version: Number: 1032 Reaction definition о Reagent / Sample о Validity checks Reaction mode: Rate down Primary Secondary Read times Wavelength: 340 / 548 Main: Last required read: 33 Flex: Absorbance range: Color correction: Sample blank type: None о Reaction definition Reagent / Sample о Validity checks R1 R2 Reagent: AALT9 Reagent volume: Diluent: Saline Water volume: Diluent dispense mode: Type 0 Dispense mode: Type 0 Type 0 Diluted Default Dilution name Sample sample Diluent Water Dilution factor dilution STANDARD : 6.0 = 1:1.00 1:5 : = 1:5.00 о : = о о Reaction definition о Reagent / Sample Validity checks Reaction check: None Configure assay parameters SmartWash о General о Calibration SmartWash о Results о Interpretation Assay: A-ALT COMPONENT REAGENT / ASSAY WASH Volume Replicates Cuvette Trig 10% Detergent B*** 345 *** Select Detergent B for software prior to Version 2.2. Configure assay parameters Results о General о Calibration о SmartWash Results о Interpretation Assay: A-ALT Result units: U/L Assay defaults: Low-Linearity: 6 ** High-Linearity: 2855 Gender and age specific ranges:* GENDER AGE (UNITS) NORMAL EXTREME Either (Y) 0 55 Configure result units Assay: A-ALT Version: Result units: U/L Decimal places: 0 [Range 0 4] Correlation factor: Intercept: Rate linearity %: 10 Configure assay parameters Calibration о General Calibration о SmartWash о Results о Interpretation Assay: A-ALT Calibration method: Factor Factor: Calibrators о Volumes о Intervals о Validity checks Calibrator set: Calibrator level: Concentration: None Blank: Water 0 Replicates: 3 [Range 1 3] о Calibrators Volumes о Intervals о Validity checks Calibrator: Diluted Calibrator level Sample sample Diluent Water Blank: Water 6.0 о Calibrators о Volumes Intervals о Validity checks Calibration intervals: Full interval: 720 (hours) о Calibrators о Volumes о Intervals Validity checks Blank absorbance range: Due to differences in instrument systems and unit configurations, version numbers may vary. **The linear low value (Low-Linearity) is LOQ rounded up to the number of decimal places defined in the decimal places parameter field. 5

6 AEROSET SYSTEM ASSAY PARAMETERS Activated Alanine Aminotransferase Serum/Plasma Conventional and SI Units Assay Configuration: Outline Page Assay Name Assay # Line A-ALT 32 B-Line Quantitative Ranges Min Text Min Panic-L L-Reference-H Panic-H Max Max Text * 0.0* * * 6** L-Linear Range-H 2855 Reference Ranges* Age Male Female 0 Year 0 Year 0 Year Qualitative Ranges N/A Assay Configuration: Base Page Reaction Mode Wavelength-Prim/Sec Read time-main/flex Linearity % RATE DOWN 340 / / Sample Blank Test Blank Read Time Abs Window Abs Limits ( ) S.Vol DS.Vol D.Vol W.Vol Standard Rgt Name/Pos Dil Diluent: Diluent D 18* Dil Type# 0 Rgt Name/Pos R.Vol W.Vol Type# Reagent 1 AALT961 * Reagent 2 AALT962 * Reaction Check Read Time A/B Range Minimum 1 1 / Factor/Intercept Decimal Places Units 1.0 / U/L Assay Configuration: Calibration Page Calib Mode Factor Interval (H) Factor Blank/Calib Replicates Span Span Abs Range 3 / 0 BLK Sample S.Vol DS.Vol D.Vol W.Vol Blk Abs Range BLK Water C Cal Deviation C Assay Configuration: SmartWash Page Rgt Probe Reagent Wash Vol Cuvette Assay Name Wash Vol Sample Probe Wash Water Refer to Assay Configuration in Section 2 of the AEROSET System Operations Manual for information regarding assay parameters. * User defined or instrument defined. ** The linear low value (L-Linear Range) is LOQ rounded up to the number of decimal places defined in the decimal places parameter field. Rgt Name listed is for 8L For 8L92-20, change Reagent 1 name to AALT951 and change Reagent 2 name to AALT952. 6

7 7

8 8